Geron Corp (GERN)

Price$1.17

Value ScoreD

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-8.77%

Price vs S&P 500 (4W)-15.82%

VGM Score53.72

Market Capitalization$750.58M

All Metrics

Book Value / Share (Quarterly)$0.36

P/TBV (Annual)3.34x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)574.21%

Cash Flow / Share (Quarterly)$-0.20

Price vs S&P 500 (YTD)-19.52%

Gross Margin (TTM)97.33%

Net Profit Margin (TTM)-34.32%

EPS (TTM)$-0.10

10-Day Avg Trading Volume9.88M

EPS Excl Extra (TTM)$-0.10

Revenue Growth (5Y)274.39%

EPS (Annual)$-0.13

ROI (Annual)-17.58%

Gross Margin (Annual)97.42%

Net Profit Margin (5Y Avg)-21993.22%

Cash / Share (Quarterly)$0.49

Revenue Growth QoQ (YoY)30.89%

ROA (Last FY)-14.64%

Revenue Growth TTM (YoY)68.64%

EBITD / Share (TTM)$-0.08

ROE (5Y Avg)-88.55%

Operating Margin (TTM)-26.37%

Cash Flow / Share (Annual)$-0.17

P/B Ratio3.28x

P/B Ratio (Quarterly)4.17x

Net Income / Employee (Annual)$-323,600

EV / Revenue (TTM)4.75x

Net Interest Coverage (TTM)-4.74x

ROA (TTM)-12.09%

EV / EBITDA (TTM)1981.47x

EPS Incl Extra (Annual)$-0.13

Current Ratio (Annual)4.66x

Quick Ratio (Quarterly)4.87x

3-Month Avg Trading Volume17.06M

52-Week Price Return-25.00%

Revenue / Employee (TTM)$760,100

Tangible BV / Share (Quarterly)$2.47

P/S Ratio (Annual)4.08x

Asset Turnover (Annual)0.32x

52-Week High$2.01

Operating Margin (5Y Avg)-22678.24%

EPS Excl Extra (Annual)$-0.13

CapEx CAGR (5Y)-34.29%

Tangible BV CAGR (5Y)27.31%

26-Week Price Return-0.85%

Quick Ratio (Annual)3.58x

13-Week Price Return-17.61%

Total Debt / Equity (Annual)1.10x

Current Ratio (Quarterly)6.78x

Enterprise Value$931.29M

Revenue / Share Growth (5Y)214.25%

Asset Turnover (TTM)0.35x

Book Value / Share Growth (5Y)-12.26%

Revenue / Employee (Annual)$712,700

Pretax Margin (Annual)-45.41%

Cash / Share (Annual)$0.56

3-Month Return Std Dev62.19%

Net Income / Employee (TTM)$-260,900

ROE (Last FY)-36.97%

Net Interest Coverage (Annual)-3.42x

EPS Basic Excl Extra (Annual)$-0.13

P/FCF (TTM)26.47x

Receivables Turnover (TTM)5.37x

Total Debt / Equity (Quarterly)1.09x

EPS Incl Extra (TTM)$-0.10

Receivables Turnover (Annual)0.24x

ROI (TTM)-13.75%

P/S Ratio (TTM)3.83x

Pretax Margin (5Y Avg)-21993.22%

Revenue / Share (Annual)$0.28

Tangible BV / Share (Annual)$2.47

Forward P/E95.65x

Price vs S&P 500 (52W)-49.37%

Year-to-Date Return-11.36%

5-Day Price Return-3.31%

EPS Normalized (Annual)$-0.13

ROA (5Y Avg)-43.32%

Net Profit Margin (Annual)-45.41%

Month-to-Date Return-6.40%

Cash Flow / Share (TTM)$-0.34

EBITD / Share (Annual)$-0.10

Operating Margin (Annual)-37.30%

LT Debt / Equity (Annual)1.03x

ROI (5Y Avg)-56.16%

LT Debt / Equity (Quarterly)1.00x

EPS Basic Excl Extra (TTM)$-0.10

P/TBV (Quarterly)3.34x

P/B Ratio (Annual)3.73x

Inventory Turnover (TTM)0.06x

Pretax Margin (TTM)-34.32%

Book Value / Share (Annual)$0.35

Price vs S&P 500 (13W)-25.86%

Beta0.64x

P/FCF (Annual)81.41x

Revenue / Share (TTM)$0.29

ROE (TTM)-27.95%

52-Week Low$1.04

vGradeD

gGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.01est. -0.02

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.92

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
GERNGeron Corp	D	A	D	$1.17
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Geron is a biopharmaceutical company focused on telomerase inhibitors for blood cancers. Its lead product, RYTELO (imetelstat), is approved in the United States and European Union for transfusion-dependent lower-risk myelodysplastic syndromes. The company is conducting Phase 3 testing in myelofibrosis and advancing studies in other hematologic malignancies.